Lack of Benefit With Idalopirdine for Alzheimer Disease: Another Therapeutic Failure in a Complex Disease Process

Alzheimer disease is a large and growing public health problem that has prompted governments around the world, including in the United States, to develop national plans to address the disease.¹ However, medications approved for the treatment of Alzheimer disease provide little symptomatic benefit, and the most recent approval by the US Food and Drug Administration occurred in 2003 (not including reformulations).